| scholarly article | Q13442814 |
| P50 | author | Thomas W Geisbert | Q60061444 |
| Joan B Geisbert | Q109874939 | ||
| P2093 | author name string | C J Peters | |
| J W LeDuc | |||
| M Bray | |||
| P B Jahrling | |||
| J W Huggins | |||
| N K Jaax | |||
| J R Swearengen | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Orthoebolavirus zairense | Q10538943 |
| P304 | page(s) | S224-34 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | |
| P478 | volume | 179 Suppl 1 |
| Q30384090 | "Filoviruses": a real pandemic threat? |
| Q34539842 | A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses |
| Q56786373 | A guided tour through the antiviral drug field |
| Q36844471 | A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals |
| Q36295162 | A survey of antiviral drugs for bioweapons |
| Q34220503 | Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates |
| Q28485505 | Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species |
| Q40155280 | Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease |
| Q40175069 | Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis |
| Q34479906 | Against the clock towards new Ebola virus therapies |
| Q30148647 | Animal Models of Ebolavirus Infection |
| Q40056187 | Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. |
| Q36994087 | Antibody therapeutics for Ebola virus disease |
| Q35889586 | Antivirals and antiviral strategies |
| Q40625399 | Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses |
| Q35598919 | Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak |
| Q38708817 | Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens |
| Q39413473 | Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells |
| Q37190830 | Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection |
| Q37282815 | Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever |
| Q26775412 | Convalescent plasma: new evidence for an old therapeutic tool? |
| Q37945233 | Correlates of immunity to filovirus infection |
| Q33964682 | Defense against filoviruses used as biological weapons |
| Q24612811 | Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques |
| Q34435069 | Detection of cell-cell fusion mediated by Ebola virus glycoproteins |
| Q64360460 | Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection |
| Q36379337 | Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses |
| Q36655280 | Development of novel entry inhibitors targeting emerging viruses |
| Q36379341 | Development of treatment strategies to combat Ebola and Marburg viruses |
| Q40039706 | Discovering Drugs for the Treatment of Ebola Virus. |
| Q28344889 | Early immune responses accompanying human asymptomatic Ebola infections |
| Q26798860 | Ebola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent Updates |
| Q36363253 | Ebola Virus Infection: Overview and Update on Prevention and Treatment |
| Q30251949 | Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials |
| Q35108607 | Ebola Virus: Immune Mechanisms of Protection and Vaccine Development |
| Q28475642 | Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery |
| Q34648461 | Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation |
| Q30712477 | Ebola virus can be effectively neutralized by antibody produced in natural human infection |
| Q30203249 | Ebola virus disease: What clinicians in the United States need to know |
| Q44106299 | Ebola virus disease: an update on post-exposure prophylaxis |
| Q24629282 | Ebola virus entry requires the host-programmed recognition of an intracellular receptor |
| Q24794365 | Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells |
| Q34583832 | Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge |
| Q34792924 | Ebola virus-like particles protect from lethal Ebola virus infection |
| Q37584926 | Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways. |
| Q27490991 | Ebolavirus glycoprotein structure and mechanism of entry |
| Q21131616 | Effective post-exposure treatment of Ebola infection |
| Q57092615 | Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs |
| Q36233840 | Efficacy of the Rabbit Polyclonal Anti-leptospira Antibody against Homotype or Heterotype Leptospira Infection in Hamster |
| Q24597625 | Emerging targets and novel approaches to Ebola virus prophylaxis and treatment |
| Q57092495 | Enhancement of Ebola virus infection by seminal amyloid fibrils |
| Q36015461 | Evaluation in nonhuman primates of vaccines against Ebola virus |
| Q36433538 | Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. |
| Q35260239 | Evasion of the interferon-mediated antiviral response by filoviruses |
| Q35971398 | Exotic emerging viral diseases: progress and challenges |
| Q33957838 | Experimental therapy of filovirus infections |
| Q44090031 | Fighting the Ebola virus |
| Q35048254 | Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine |
| Q38599899 | Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus |
| Q36452418 | Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats |
| Q26783063 | Filoviruses: One of These Things is (not) Like the Other |
| Q44091237 | Filoviruses: recent advances and future challenges |
| Q34173952 | Forty years of the war against Ebola |
| Q25256700 | Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. |
| Q34434866 | Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence |
| Q39259533 | High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus |
| Q36858879 | How Ebola and Marburg viruses battle the immune system |
| Q34464533 | Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses |
| Q49917351 | Immune barriers of Ebola virus infection |
| Q37213207 | Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates |
| Q30238887 | Immunobiology of Ebola and Lassa virus infections |
| Q36977508 | Immunopathology of highly virulent pathogens: insights from Ebola virus |
| Q38924824 | Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. |
| Q34345308 | Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells |
| Q30832644 | Infergen Stimulated Macrophages Restrict Mycobacterium tuberculosis Growth by Autophagy and Release of Nitric Oxide. |
| Q44105836 | Integrating clinical research into epidemic response: the field perspective in the Ebola experience |
| Q31055717 | Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective |
| Q36287337 | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| Q38709267 | Interferon-β and Interferon-γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays |
| Q36936330 | Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever |
| Q28550929 | Interferon-γ Inhibits Ebola Virus Infection |
| Q33987611 | Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses |
| Q27490714 | Marburg Virus Evades Interferon Responses by a Mechanism Distinct from Ebola Virus |
| Q27011569 | Mouse models for filovirus infections |
| Q21562420 | Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses |
| Q33269796 | Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys |
| Q39234323 | Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor |
| Q40051414 | Nonhuman Primate Models of Ebola Virus Disease |
| Q40332893 | Nonhuman primates as models for the discovery and development of ebolavirus therapeutics |
| Q21245402 | Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga |
| Q24550699 | Passive immunity in prevention and treatment of infectious diseases |
| Q33840716 | Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. |
| Q35843254 | Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection |
| Q35843339 | Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells |
| Q35853406 | Pathogenesis of filoviral haemorrhagic fevers |
| Q39601175 | Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques |
| Q35107644 | Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy |
| Q33826350 | Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product |
| Q47548534 | Post-exposure treatments for Ebola and Marburg virus infections |
| Q35882397 | Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. |
| Q34519791 | Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment |
| Q34526756 | Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference |
| Q34022606 | Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study |
| Q36404178 | Potential vaccines and post-exposure treatments for filovirus infections |
| Q39683688 | Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody |
| Q40371592 | Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus. |
| Q97905075 | Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment |
| Q30230272 | Progress towards the treatment of Ebola haemorrhagic fever |
| Q36088118 | Prospects for immunisation against Marburg and Ebola viruses |
| Q33865376 | Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein |
| Q40466798 | Protective efficacy of neutralizing antibodies against Ebola virus infection. |
| Q39821574 | RIG-I activation inhibits ebolavirus replication |
| Q37093682 | Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome |
| Q36183762 | Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant |
| Q38047077 | Regulators of innate immunity as novel targets for panviral therapeutics |
| Q40045378 | Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review |
| Q34426585 | Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp |
| Q64229700 | Role of Type I Interferons on Filovirus Pathogenesis |
| Q38877091 | Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes |
| Q34606818 | Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus |
| Q38666317 | Small Animal Models for Studying Filovirus Pathogenesis |
| Q36043209 | State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus |
| Q91908893 | Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES) |
| Q64360249 | Structural basis of broad ebolavirus neutralization by a human survivor antibody |
| Q40283373 | Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies |
| Q24594601 | Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb |
| Q34971349 | Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies |
| Q26778003 | The Role of Cytokines and Chemokines in Filovirus Infection |
| Q39370363 | The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. |
| Q35634367 | The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. |
| Q39083915 | The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication |
| Q33955164 | The pathogenesis of Ebola hemorrhagic fever |
| Q37982883 | The yin and yang of viruses and interferons |
| Q37807782 | Therapeutic use of immunoglobulins |
| Q38980947 | Therapeutics for postexposure treatment of Ebola virus infection |
| Q33974706 | Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys |
| Q34460182 | Treatment of ebola virus disease |
| Q40621627 | Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor |
| Q36482804 | Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers |
| Q34509643 | VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice |
| Q40220227 | Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse |
| Q35143290 | Vaccine research efforts for filoviruses |
| Q40052567 | Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. |
| Q21131585 | Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates |
| Q34598925 | Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses |
| Q38914896 | Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing? |
| Q34398543 | Viral hemorrhagic fever hazards for travelers in Africa |
| Q35125834 | Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection |
| Q40231241 | mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms |
Search more.